Member Info for Kevinl1977

I like the subtle ramp BG

Several deaths, for both treatments.
‘concluded that the medicines’ benefits are greater than their risks for their approved uses. ‘
If that’s the benchmark, then you would expect better from SNG.

Tommy
You getting some overtime in?
You shouldn’t be working this late on a Saturday

Gggg
Many thanks for the post, another interesting report on the benefits of IFNb.

Skippy
‘Everyone invested has to accept that we could lose our entire investment. That should be everyone’s starting position on any investment in AIM.’
That is incorrect! How can you lose your entire investment, even if results are not what we are expecting?
Their is a whole host of respiratory markets that SNG can still support, especially COPD.
Brand has just explained it in more detail.
Your investment strategy is up to you and I understand why you think this way.
I’m listening to finncap, polygon, RM, SSH and have based my investment on their feedback.
GLA

Brand
My thoughts exactly

Pattagucci
How can the results, that are double blinded, be priced in yet?
This is not EasyJet just before the summer, where tickets are expected to be sold in their thousands.
Upon results, it will either drop significantly if the data is poor or rise significantly, if the results are good.

Good point made chaps.
Have a great weekend.

Yes, European cases are rising fast. Lockdowns and partial lockdowns in place.
We need SNG to come good to save more lives.
Roll on EUA.

Thanks all, yet again!

To all LTHs
We all know there will be many more of these 1 message wonders between now and results.
Filtered

After seeing what geovanni has posted about its failings, I’m particularly confused, albeit a little more content.
Thanks all.

Matt
Many thanks for replying.
I’ve just seen a selection of articles around the same drug today, which panicked me.
I know it doesn’t change the situation with our drug, but how the media crank it up for the big pharmas is unreal.
I hope we get the same airtime, if our drug achieves the results we are expecting in early 2022.
Thanks again.

No worries Matt; thanks for the reply.

Many thanks Prion.
I sincerely hope you’re right.
It’s amazing how the big pharmas get everything rushed through at breakneck speed.
I also spotted the numbers are different across different media platforms.
Much appreciated.

Matterhorn
I know I’ll get an honest answer from you.
This concerns me, hence the post.
Come across this on mainstream media today and I’m sure others have seen it.
Although the numbers seem to be different across the various platforms, they are impressive. These haven’t been peer reviewed mind, although carries the power of the big pharma.
The treatment appears to be good for hospitalised patients, and the patients administered in P3 is 900. It also covers other illnesses.
Is this a potential threat to us, or is the difficulty of injection and the fact it hasn’t been peer reviewed yet meaning it is nothing to panic about?
Appreciate your view.

https://www.msn.com/en-gb/health/medical/astrazenecas-new-covid-antibody-treatment-more-effective-than-vaccines-after-six-months/ar-AAQR0pT?ocid=mailsignout&li=BBoPWjQ

The boyg
0 deaths, more like !!

Seaboy
You’re singing off a similar hymn sheet to me.
My ideal scenario would be:
SP @ £10-15 - sell enough shares to make £100k for a renovation project in summer 2022.
Keep the rest in play, until JV/TO and see what progress is being made by the company.
Pull everything out, minimise tax bill as much as possible, move on.
GLA

Winit
I think this gives it away!
Akron will support the future clinical and commercial development of SNG001 through the provision of its IFN-beta in Synairgen’s formulation. “Akron’s expertise in recombinant protein manufacturing and large-scale production capacity add significant value to our further development and commercialisation of SNG001,” commented Synairgen CEO Richard Marsden.